Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
ConclusionsTepotinib demonstrated robust and durable clinical efficacy in Japanese patients with advanced NSCLC harbouringMET exon 14 skipping, identified by either liquid or tissue biopsy. The main adverse events, blood creatinine increase and peripheral oedema, were manageable.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Study